Kolon Life Science Inc

Kolon Life Science Inc maintains a relatively strong capital structure with a debt-to-equity ratio of 0.18, indicating a low reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.64, suggesting that its current liabilities exceed its current assets. Free cash flow is negative at -3.74 billion KRW, which may signal reinvestment in operations or capital expenditures. The price-to-book ratio of 1.22 and price-to-tangible-book ratio of 1.22 suggest that the company's market value is slightly above its book value.

Profitability metrics show a return on equity (ROE) of 4.27% and a return on assets (ROA) of 2.73%, which are below the industry median for pharmaceutical companies. The company's gross profit margin is 26.75% (55.89 billion KRW gross profit on 208.98 billion KRW revenue), and its operating margin is 7.68% (16.05 billion KRW operating income on 208.98 billion KRW revenue). These figures indicate that the company is generating profits but at a lower efficiency compared to industry peers.

Geographically, Kolon Life Science Inc's revenue is concentrated in South Korea, with no disclosed international revenue segments. The company operates in a single business segment focused on pharmaceuticals, which may limit diversification benefits. The lack of segmental or geographic diversification increases exposure to local market risks, including regulatory changes and domestic economic conditions.

The company's growth trajectory is modest, with no disclosed revenue growth rates in the latest financials. The outlook for the current fiscal year (FY) and the next FY is neutral, with no significant revenue deltas projected. The company's capital expenditures of -38.39 billion KRW suggest a focus on cost management or asset optimization rather than expansion.

Risk factors include a medium liquidity risk due to the current ratio of 0.64 and a negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential in the basic shares outstanding. The company has not disclosed any recent equity issuance or ATM/shelf registration that would suggest near-term dilution pressure.

Recent events include the filing of the latest financial statements, which show a net income of 24.96 billion KRW. No material events or earnings call transcripts have been disclosed in the available data. The company's financial performance appears stable, but the lack of recent strategic announcements or product launches may indicate a conservative operational approach.